Premium
Glucocorticoids in juvenile idiopathic arthritis
Author(s) -
Malattia Clara,
Martini Alberto
Publication year - 2014
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12436
Subject(s) - methotrexate , medicine , arthritis , juvenile , disease , drug , macrophage activation syndrome , immunology , pharmacology , genetics , biology
Although the use of corticosteroids in juvenile idiopathic arthritis (JIA) is now much more limited owing to the availability of methotrexate and biological agents, there are clinical scenarios where it is still indicated. For example, corticosteroids may be indicated for intraarticular injections to prevent joint deformities, as a “bridge” drug to relieve symptoms in polyarticular disease while waiting for methotrexate and biologics to exert their full therapeutic effects, and in the treatment of chronic iridocyclitis, macrophage activation syndrome, and systemic JIA, although the advent of interleukin (IL)‐1 and IL‐6 blockers has greatly reduced the latter indication.